EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Cluster-Randomized Controlled Trial of Enhanced Carbapenem-Resistant Enterobacterales Prevention Program in General Medicine Wards, Siriraj Hospital

Apiradee Taweesuk, Pinyo Rattanaumpawan iD, Siriporn Rachakhom, Walaiporn Wangchinda iD, Susan Assanasen iD, Visanu Thamlikitkul iD

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf523 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Apiradee Taweesuk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Tha…. Hauptthemen laut MEDLINE: Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae, Infection Control, Cross Infection. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, Health Systems Research Institute, Thailand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Carbapenem-resistant Enterobacterales (CRE) colonization is a major risk factor for infection. Most infection prevention and control (IPC) strategies rely on private-room isolation, but evidence of their effectiveness in resource-limited settings is scarce.

Methods

From February to October 2021, we conducted a cluster-randomized controlled trial in 6 general medical wards at Siriraj Hospital, enrolling adults with ≥1 CRE risk factor. Wards were randomized to standard infection control care (sIC) or an enhanced CRE prevention program (eIC) comprising sIC plus monthly staff education, real-time notifications of CRE acquisition, and contact-precaution reminders. Active stool/rectal CRE surveillance was performed at enrollment and weekly. Primary outcomes were the CRE acquisition incidence and CRE acquisition–free time.

Results

A total of 363 patients were included: 174 in the intervention group (1684 patient-days) and 189 in the control group (1517 patient-days). The cumulative incidence of CRE acquisition was slightly lower in the intervention group (36.8% vs 46.6%; P = .06), with a significantly lower incidence rate per patient-day (0.038 vs 0.058; P = .007). In a post hoc analysis excluding acquisitions within 24 hours, the cumulative incidence was similar between groups (25.7% vs 33.6%; P = .16). The probability of remaining CRE-free showed an unadjusted hazard ratio (HR) of 0.72 [95% CI, 0.52–1.00; P = .05]. After adjusting for prior antibiotic use, the adjusted HR was 0.75 [95% CI, 0.54–1.05; P = .09]. There were no differences in all-cause mortality or length of hospital stay.

Conclusions

Carbapenem-resistant Enterobacterales acquisition incidence was high in this setting. The enhanced CRE prevention program tended to reduce CRE acquisition and prolong CRE-free survival. Larger studies are needed to explore benefits on morbidity and mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enterobacteriaceae InfectionsCarbapenem-Resistant EnterobacteriaceaeInfection ControlCross InfectionHumansFemaleMaleMiddle AgedAgedIncidenceAdultCarbapenemsAnti-Bacterial AgentsRisk FactorsThailandHospitals

Stichwörter der Autor:innen

active surveillancecarbapenem-resistant Enterobacteralescolonizationinfection control

Substanzen

CarbapenemsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Centre for Nosocomial Infection Control, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

ORCID-Profile: Pinyo Rattanaumpawan, Walaiporn Wangchinda, Susan Assanasen, Visanu Thamlikitkul

Förderung

  • Faculty of Medicine Siriraj Hospital
  • Mahidol University, Bangkok, Thailand
  • Health Systems Research Institute, Thailand

Zitieren

APA

Taweesuk, A., Rattanaumpawan, P., Rachakhom, S., Wangchinda, W., Assanasen, S., & Thamlikitkul, V. (2025). Cluster-Randomized Controlled Trial of Enhanced Carbapenem-Resistant Enterobacterales Prevention Program in General Medicine Wards, Siriraj Hospital. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf523

Vancouver

Taweesuk A, Rattanaumpawan P, Rachakhom S, Wangchinda W, Assanasen S, Thamlikitkul V. Cluster-Randomized Controlled Trial of Enhanced Carbapenem-Resistant Enterobacterales Prevention Program in General Medicine Wards, Siriraj Hospital. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf523

BibTeX
@article{Taweesuk2025,
  author = {Taweesuk, Apiradee and Rattanaumpawan, Pinyo and Rachakhom, Siriporn and Wangchinda, Walaiporn and Assanasen, Susan and Thamlikitkul, Visanu},
  title = {Cluster-Randomized Controlled Trial of Enhanced Carbapenem-Resistant Enterobacterales Prevention Program in General Medicine Wards, Siriraj Hospital},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf523}
}
Kostenlos starten →